← All trials
NCT05868967
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2023
- Primary completion
- May 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- May 22, 2023
- Last posted
- May 22, 2023
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Daewoong Pharmaceutical Co. LTD.Lead sponsor
- Beijing Boren HospitalOverall official - principal investigator
- Beijing Boren HospitalOfficial
- Shanghai Haini Pharmaceutical Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.